mMTORC1 activation in childhood ependymoma and response to sirolimus

Journal of Neuro-Oncology

Volumn 103, Issue 3, 2011, Pages 797-801

  Bowers, Daniel C ^a,b,c   Kucejova, Blanka ^a,b   Margraf, Linda ^a   Gargan, Lynn ^c   Brugarolas, James ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c CHILDREN S MEDICAL CENTER   (United States)

Author keywords

Ependymoma; mTORC1; Rapamycin; Sirolimus

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CYCLOPHOSPHAMIDE; ETOPOSIDE; FENOFIBRATE; IFOSFAMIDE; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RAPAMYCIN; S6 KINASE; THALIDOMIDE; VINCRISTINE; VORINOSTAT; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; PROTEIN S6; SERINE; TARGET OF RAPAMYCIN KINASE;

ABSENCE OF SIDE EFFECTS; ARTICLE; BRAIN SURGERY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; CHEMOSENSITIVITY; CHILD; COMPUTER ASSISTED RADIOTHERAPY; DRUG RESPONSE; DRUG TOLERABILITY; EPENDYMOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRESCHOOL CHILD; PROTEIN PHOSPHORYLATION; SPINAL CORD METASTASIS; BRAIN TUMOR; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING;

BRAIN NEOPLASMS; CHILD, PRESCHOOL; EPENDYMOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; RIBOSOMAL PROTEIN S6; SERINE; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 79959773638     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0455-7     Document Type: Article

References (19)

1. Merchant TE, Mulhern RK, Krasin MJ et al (2004) Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 22:3156-3162 (Pubitemid 41103730)
2. Bouffet E, Capra M, Bartels U (2009) Salvage chemotherapy for metastatic and recurrent ependymoma of childhood. Childs Nerv Syst 25:1293-1301
3. Goldwein JW, Glauser TA, Packer RJ et al (1990) Recurrent intracranial ependymomas in children. Survival, patterns of failure, and prognostic factors. Cancer 66:557-563
4. Sangra M, Thorp N, May P et al (2009) Management strategies for recurrent ependymoma in the pediatric population. Childs Nerv Syst 25:1283-1291
5. Merchant TE, Boop FA, Kun LE et al (2008) A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys 71:87-97 (Pubitemid 351491399)
6. Kieran MW, Turner CD, Rubin JB et al (2005) A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 27:573-581 (Pubitemid 41697342)
7. Brugarolas J, Lotan Y, Watumull L et al (2008) Sirolimus in metatastic renal cell carcinoma. J Clin Oncol 26:3457-3460
8. Stallone G, Schena A, Infante B et al (2005) Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352:1317-1323 (Pubitemid 40411498)
9. Wagner AJ, Malinowska-Kolodziej I, Morgan JA et al (2010) Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 28:835-840
10. Wolff N, Kabbani W, Bradley T et al (2010) Sirolimus and temsirolimus for epithelioid angiomyolipoma. J Clin Oncol 28:e65-e68
11. Bissler JJ, McCormack FX, Young LR et al (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140-151
12. Franz DN, Leonard J, Tudor C et al (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490-498 (Pubitemid 43358069)
13. Motzer RJ, Molina AM (2009) Targeting renal cell carcinoma. J Clin Oncol 27:3274-3276
14. Witzig TE, Geyer SM, Ghobrial I et al (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347-5356 (Pubitemid 46206988)
15. Galanis E, Buckner JC, Maurer MJ et al (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23:5294-5304 (Pubitemid 46206983)
16. Fouladi M, Laningham F, Wu J et al (2007) Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 25:4806-4812 (Pubitemid 350086485)
17. Houghton PJ, Morton CL, Kolb EA et al (2008) Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50:799-805 (Pubitemid 351354788)
18. Iwenofu OH, Lackman RD, Staddon AP et al (2007) Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 21:231-237 (Pubitemid 351304283)
19. Cho D, Signoretti S, Dabora S et al (2007) Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 5:379-385 (Pubitemid 47584475)